Antiviral market
| $50b | Viral treatment market |
| $1.2-3b | HIV-1 cure project revenue |
| $120m | HIV-1 program valuation |
| HIV | $30.89b |
| SARS-CoV-2 | $2.7b |
| Influenza | $6.59b |
| Next pandemic | $?b |
COMPETITIVE ADVANTAGES
Biomedrex proprietary software discovery platform coupled with our in-house capabilities grants full ownership of the development lifecycle all the way up to clinical studies. Reusable company IP and the adaptability of the drug complex greatly reduce the investors risks.
- Candidates for new virus ready for testing in days
- Massive reductions in cost and time
- All experimental validation done in-house with proprietary assays
- Possible to license experimentally validated candidates to Pharma
- Accelerated regulatory pathways viable